Detailed Narrative
Q1 FY26 Performance Overview
Fredun Pharmaceuticals delivered a robust performance in Q1 FY26, with revenue growing by 52% year-on-year to INR 119.86 crores. This strong top-line growth translated into a 62% increase in EBITDA, reaching INR 16.99 crores, and an expanded EBITDA margin of 14.18%. Net profit saw a significant rise of 64% year-on-year to INR 6.77 crores, resulting in an EPS of INR 14.33, up over 63%.
Strategic Shift to New Age Business and Branding
The company is undergoing a strategic transition from an OEM manufacturer to a holistic healthcare company, focusing on branded generics and new age businesses. By January 2029, the goal is for every product from their ecosystem to be Fredun branded. New age businesses, including pet care, nutrition, mobility, and wellness, are projected to grow at a 35-40% CAGR, and are expected to contribute over 51% of total revenue by FY32. This shift aims to improve gross margins, which are currently above 50% for new age products.
Pet Care Ecosystem Expansion
Fredun is building a comprehensive pet care ecosystem under its Freossi brand, offering a range of products from nutraceuticals to diagnostics. A key move in Q1 was the acquisition of One Pet Stop, a tech-enabled doorstep grooming platform, providing direct access to 4,000 pet owners in the MMRDA region for cross-selling. Additionally, the company launched India's first 24x7 dedicated pet diagnosis center, equipped with advanced imaging, with a potential to generate INR 15 crores annually per center at a 20-25% net margin. Plans are in place to expand this diagnostic network across major Indian metros, with one more center planned for North Mumbai by year-end.
Generics Business and Product Pipeline
The generics division, including Fredun Gx, is a significant focus, with plans to grow Fredun Gx revenue from INR 55-60 crores in FY25 to INR 85 crores this year, and further to INR 150 crores the following year. The long-term target for the Gx line is INR 250-300 crores within the next 12 quarters. The company has over 1,200 products under registration, with 15-20% of these being new molecules specific to certain geographies, ensuring a continuous pipeline for growth in the vintage business, which is expected to grow 15-20% year-on-year for the next 7-9 years.
Working Capital Management and Fundraising
The company's inventory currently stands at over INR 200 crores, and receivables were under INR 100 crores as of July 31st. Management acknowledges rising debtor days due to increased sales and market practices, aiming to stabilize them at 125-127 days within 6-8 quarters. Inventory days are also expected to align at 125-130 days within 6-7 quarters. While the company has grown significantly without external funding, it plans to raise funds soon to support its ambitious growth and expansion initiatives.